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Abstract. Heterozygous hemoglobin S (HbAS), or sickle trait, protects children from life-threatening falciparum malaria,
potentially by attenuating binding of Plasmodium-infected red blood cells (iRBCs) to extracellular ligands. Such binding
is central to the pathogenesis of placental malaria (PM). We hypothesized that HbAS would be associated with reduced
risks of PM and low birth weight (LBW). We tested this hypothesis in 850 delivering women in southern Malawi. Parasites
were detected by polymerase chain reaction in placental and peripheral blood, and placentae were scored histologically
for PM. The prevalence of HbAS was 3.7%, and 11.2% of infants were LBW (< 2,500 g). The prevalence of Plasmodium
falciparum was 12.7% in placental and 8.5% in peripheral blood; 24.4% of placentae demonstrated histological evidence
of P. falciparum. HbAS was not associated with reduced prevalence of P. falciparum in placental (odds ratio [OR]:
1.27, 95% confidence interval [CI]: 0.50–3.23, P = 0.61) or peripheral blood (OR: 2.53, 95% CI: 1.08–2.54, P = 0.03),
prevalence of histological PM (OR: 0.97, 95% CI: 0.40–2.34, P = 0.95), or prevalence of LBW (OR: 0.82, 95% CI:
0.24–2.73, P = 0.74). Mean (standard deviation) birth weights of infants born to HbAS (2,947 g [563]) and, homozygous
hemoglobin A (2,991 g [465]) mothers were similar. Across a range of parasitologic, clinical, and histologic outcomes,
HbAS did not confer protection from PM or its adverse effects.
INTRODUCTION
Heterozygous hemoglobin S (HbAS), or sickle trait, con-
sistently protects African children from clinical manifestations
of falciparum malaria.1–4 Across ethnic groups and transmis-
sion settings, HbAS reduces the risk of severe malaria by
91% and the risk of uncomplicated malaria by 31% but offers
no protection against asymptomatic parasitemia.2 Despite this
consistent biological effect, the underlying mechanisms of pro-
tection are incompletely understood. Several hypotheses have
been investigated in vitro, including 1) a restriction of para-
site growth within HbAS red blood cells (RBCs) owing to
increased oxidative damage stress to RBCs5; 2) more rapid
clearance and destruction of parasitized HbAS RBCs6; and
3) abnormal or reduced display of the parasite’s major cyto-
adherence ligand and virulence factor, Plasmodium falciparum
erythrocyte membrane protein 1 (PfEMP1), resulting in attenu-
ated binding of the infected RBCs (iRBCs) to extracellular
ligands.2,5,7 Although HbAS offers a model of malaria protec-
tion with which to identify mechanisms of parasite pathogene-
sis, there is a paucity of mechanistic investigations in vivo.
Placental malaria offers a distinct molecular and cellular
in vivo model of P. falciparum pathogenesis. In malaria-
endemic areas, antenatal P. falciparum infections can ulti-
mately manifest as placental malaria, in which iRBCs sequester
in the intervillous space.8,9 This placental sequestration results
from the binding of iRBCs to receptors on the placenta such
as placental chondroitin sulfate A (CSA). This interaction
with CSA is mediated by the expression on the iRBC surface
of the conserved PfEMP1 variant VAR2CSA. Expression of
VAR2CSA is upregulated in iRBCs selected for adherence to
CSA, and attenuation of var2csa expression abrogates adher-
ence to CSA.10–12 Therefore, placental malaria serves as an
in vivo model of P. falciparum sequestration.
The aim of this study was to investigate the association
between HbAS and placental malaria. Because adherence of
iRBCs is critical for placental sequestration in vivo and is
attenuated by HbAS in vitro, we hypothesized that HbAS
would reduce placental sequestration and therefore the prev-
alence of placental malaria. In addition, because placental
malaria reduces birth weight, we further hypothesized that
HbAS would be associated with increased birth weight.
METHODS
Study design and population. A cross-sectional survey of
consecutive delivering women was conducted between Novem-
ber 2009 and January 2011 at three health facilities near
Blantyre, Malawi. Malaria transmission is perennial in these
districts with peaks observed during the monsoon season
(November–March). Plasmodium falciparum causes over
> 90% of all malaria infections, and Plasmodium malariae
and Plasmodium ovale infections have also been reported.
Eligible women were those with singleton pregnancies
who could provide written informed consent. Women were
excluded if they did not reside in the study area. National
treatment guidelines were followed to treat both women at
delivery, who tested positive for malaria parasites in periph-
eral blood and infants with parasites in cord blood. The study
protocol and consent procedures were approved by the ethical
review boards of the University of Malawi College of Medi-
cine and the Liverpool School of Tropical Medicine; testing
of de-identified specimens was approved by the University of
North Carolina.
After enrollment, demographics, human immunodeficiency
virus (HIV) status, and receipt of intermittent preventive treat-
ment in pregnancy (IPTp) with sulphadoxine–pyrimethamine
(SP) were collected from antenatal care (ANC) records. A
fingerprick blood sample was collected for storage on filter
paper as a dried blood spot (DBS). Placental tissue samples
were collected for histologic examination of P. falciparum infec-
tion and inflammation. At delivery, infant birth weight was
recorded to the nearest gram within 24 hours using a calibrated
digital scale.
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Laboratory procedures. At delivery, an incision was made
on the maternal side of the placenta to collect placental blood,
which was then stored as a DBS. Genomic DNA (gDNA) was
extracted from placental and peripheral blood DBS using 20%
Chelex (BioRad, Hercules, CA) as previously described.13 For
histologic analysis, placental tissue was collected by excising
from the maternal side a 2 × 2 × 1-cm specimen, which was
then placed in formalin and prepared and stained with Gurr’s
modified Giemsa or hematoxylin and eosin. All placental tissue
samples were examined by a trained technician using a stan-
dard 5-point scale for placental malaria and inflammation.14
Molecular tests. All samples were tested for Plasmodium
spp. parasites using two real-time polymerase chain reaction
(PCR) assays targeting the parasite 18S ribosomal DNA as
previously described.15 In brief, samples were first tested by a
genus-specific real-time PCR, and all samples testing positive
in the pan-species assay were then amplified in a speciation
assay testing for P. falciparum. A positive control consisting of
P. falciparum strain 3D7 gDNA and a negative control
consisting of water was included on each reaction plate. All
reactions were run in duplicate on the ABI 7300 Real-Time
PCR machine (Applied Biosystems, Foster City, CA). Fluo-
rescent threshold lines were manually set based on the con-
trols to eliminate background noise.
To estimate relative P. falciparum densities, all placental and
peripheral blood samples collected from women that tested
positive for P. falciparum in either specimen were then tested
in a duplex real-time PCR assay targeting the P. falciparum
lactate dehydrogenase gene (pfldh) and the human β-tubulin
gene. For this assay, we used previously described primers
and a FAM-TAMRA probe for pfldh,16 β-tubulin primers
(forward: AAG GAG GC GAT GAG CAG AT, reverse:
GCT GTC TTG ACA TTG TTG GG) at 400 nM, probe
(VIC-TTA ACG TGC AGA ACA AGA ACA GCA GCT-
TAMRA) at 600 nM, and 2 μL of gDNA template in a 12 μL
reaction; samples were amplified for 40 cycles on a BioRad
CFX384 platform on plates. In this assay, samples were tested
on plates that included a series of 13 standards tested in dupli-
cate, which contained known quantities of parasites and white
blood cells. From these standards, a standard curve was com-
puted for each plate by fitting a regression line to a plot of
the known parasite density against the ratio of the cycle quan-
tity (Cq) value for pfldh to that of human β-tubulin. Using
these standard curves for each plate, we estimated a parasite
density for each peripheral or placental blood sample that was
indexed to the amount of human DNA present. With these
estimates of parasite densities in placental and peripheral
blood, we defined the placental sequestration index as the
ratio of the density of parasites in placental blood to that in
peripheral blood.
Human β-globin gene (HBB) was typed in all women by
amplification and Sanger sequencing. The 5′ end of HBB
was amplified from gDNA using a touchdown PCR with pre-
viously published primers.17 The PCR reaction mix contained:
5 μL of 5× KAPA HiFi Buffer (KAPA Biosystems, Wilmington,
MA), 20 μM of each primer, 10 μM of dNTPs, 0.5 μL of KAPA
HiFi HotStart DNA Polymerase (KAPA Biosystems), and
5 μL of template DNA in a 25-μL reaction. The touchdown
PCR cycling conditions were as follows: 95°C for 5 minutes,
40 cycles of 98°C for 20 seconds, 75–60°C for 15 seconds
(−1°C per cycle during first 15 cycles, then 60°C for
25 cycles), and 72°C for 30 seconds, and a final extension
of 72°C for 3 minutes. PCR products were visualized on a
2% agarose gel and bidirectionally Sanger sequenced. Sam-
ples that were negative were re-amplified and sequenced.
Nucleotide sequences and chromatograms were aligned in
Sequencher (version 4.8; Gene Codes Corp., Ann Arbor, MI)
and scored manually for the A!T substitution in codon 6 that
encodes HbS.
Data analysis. We examined associations between sickle
trait and placental malaria and adverse pregnancy outcomes
such as low birth weight (LBW) in our cross-sectional cohort.
We calculated odds ratios (ORs) and their corresponding
95% confidence intervals (CIs) between HbAS and out-
comes, which included placental and peripheral malaria and
birth weight. Continuous variables (birth weight and parasite
density) were compared using Mann–Whitney test if they were
not normally distributed. Otherwise, for normally distributed
variables, Student’s t tests were used. For categorical variables
(placental malaria, peripheral malaria, histological evidence of
malaria, LBW, and gravidity), in addition to ORs, differences
in proportions were tested using a χ2 test. An α of 0.05 was
determined a priori to test for significant associations.
Since the exposure of interest in this study is a product of
Mendelian randomization, crude prevalence ORs would suf-
ficiently approximate the causal effect of the exposure on the
outcome. In this case, no measured covariates (maternal age,
gravidity, and HIV status) confound the relationship between
the exposure and outcome; hence, bivariate analysis would
estimate the association of interest. We also examined known
associations between pregnancy and malaria. Using multivari-
able logistic regression to control for known confounders, we
estimated the association between birth weight and malaria
after controlling for maternal age, HIV status, and gravidity
along with association between gravidity and malaria after con-
trolling for maternal age and HIV status. All data were first
entered into Microsoft Excel 2010 (Microsoft Corp., Redmond,
WA) and ultimately analyzed in SAS (v9.2.2; SAS Institute Inc.,
Cary, NC) or R (v3.1; The R Foundation, Vienna, Austria).
RESULTS
Study population. Of 1,206 enrolled women who delivered
in the parent IPTp study (Table 1), 854 were successfully
genotyped for HBB; and for 850 of these women, peripheral
and placental blood parasite testing and infant birth weight
were available. These women constituted the analytical popu-
lation; among these, complete placental histology readings
TABLE 1
Description of the study population (N = 850)
Age, years, mean (SD) 24.7 (5.7)
Gravidity, n (%)
Primigravid 245 (28.8)
Secundigravid 182 (21.4)
Multigravid 423 (49.8)
HIV-positive, n (%) 79 (9.3)
Birth weight, mean (SD) 2,989.9 (469.2)
Low birth weight,* n (%) 95 (11.2)
Plasmodium falciparum prevalence, n (%)
Peripheral blood 71 (8.35)
Placental blood 108 (12.7)
Any histological evidence of placental malaria
(N = 753), n (%)
207 (27.5)
SD = standard deviation.
*Defined as < 2,500 g.
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were available for 753 women. Among the 850 women, 3.7%
(N = 32) were HbAS and 0.5% (N = 4) were homozygous
hemoglobin S (HbSS). Overall, 28.8% (N = 245) were
primigravid and 9.3% (N = 79) were HIV positive. Of the
245 primigravid women, 4% (N = 10) were HbAS, and of
79 HIV-positive women, 5% were HbAS.
Malaria, birth weight, and gravidity. The overall preva-
lence detected by the presence of P. falciparum via real-
time PCR was 8.3% (N = 71) in peripheral blood and
12.7% (N = 108) in placental blood. Placental malaria,
defined as any histological evidence of P. falciparum, was
present in 27.5% (N = 207) (Table 1). The mean birth
weight of newborns was 2,990 g (standard deviation [SD] =
469.15); 11.2% (N = 95) of newborns were LBW (< 2,500 g)
(Table 2).
We first examined relationships between P. falciparum,
LBW, and gravidity. As expected, P. falciparum parasitemia
at delivery was associated with LBW. In analyses adjusted
for gravidity, maternal age, and HIV infection compared
with aparasitemic women, the prevalence of LBW was
higher among infants born to women with P. falciparum
in either peripheral blood (OR: 1.54, 95% CI: 0.79–2.99,
P = 0.20) or placental blood (OR: 1.37, 95% CI: 0.77–2.45,
P = 0.29) (Figure 1). In addition, compared with multi-
gravidae and after adjusting for maternal age and HIV
infection, P. falciparum infection in the placenta was more
common in both primigravidae (OR: 1.64, 95% CI: 0.98–2.75,
P = 0.06) and secundigravidae (OR: 1.20, 95% CI: 0.59–2.48,
P = 0.61) (Figure 2). Associations of similar magnitude and
direction were observed between gravidity and P. falciparum
infection in the peripheral blood.
Effect of HbAS on placental malaria and birth outcomes. We
next quantified the associations between HbAS and placental
malaria or LBW. The prevalence of P. falciparum in placen-
tal blood detected by real-time PCR was similar in HbAS
(15.6%) and homozygous hemoglobin A (HbAA; 12.6%)
TABLE 2
Associations between HbAS and delivery outcomes
HbAS (N = 32) HbAA (N = 814) OR* (95% CI) P value†
Real-time PCR testing
Plasmodium falciparum positive, n (%)
Peripheral blood 6 (18.8) 65 (7.7) 2.53 (1.08–5.94) 0.03
Placental blood 5 (15.6) 103 (12.6) 1.27 (0.50–3.23) 0.61
P. falciparum density (N = 76), parasites/μL, median (IQR)‡
Peripheral blood 2,467 (552–7,736) 6,118 (2,195–34,241) NA 0.14
Placental blood 5,683 (5,492–10,850) 7,008 (1,863–22,133) NA 0.85
Placental sequestration index§ 1.21 0.99 NA 0.37
Histology, n (%) (N = 753)
Any evidence of infection 7 (26.9) 200 (27.5) 0.97 (0.40–2.34) 0.95
Past infection 3 (11.5) 90 (12.4)
Chronic infection 4 (15.4) 58 (8)
Acute infection 0 52 (7.15)
No infection 19 (73.1) 527 (72.5)
Birth outcomes
Low birth weight, n (%) 3 (9.4) 92 (11.3) 0.82 (0.24–2.73) 0.74
Birth weight, g, mean (SD) 2,947 (563) 2,991 (465) NA 0.67
CI = confidence interval; HbAA = homozygous hemoglobin A; HbAS = heterozygous hemoglobin S; IQR = interquartile range; NA = not applicable; OR = odds ratio; PCR = polymerase
chain reaction; SD = standard deviation.
*Unadjusted OR; reference group for each comparison was women with HbAA.
†Computed using the Student’s t test or Mann–Whitney test for continuous outcomes and χ2 test for categorical outcomes.
‡Estimated using real-time PCR on only women with concurrent peripheral and placental infection.
§Defined as the ratio of the density of parasites in placental blood to that in peripheral blood.
FIGURE 1. Distribution of low birth weight according to maternal
malaria infection in the placental and peripheral compartments via
polymerase chain reaction.
FIGURE 2. Distribution of maternal malaria infection in the pla-
cental (PM) and peripheral (PEM) compartments via polymerase
chain reaction according to gravidity: primigravidae (PG) (N = 245) vs.
secundigravidae (SG) (N = 182) vs. multigravidae (MG) (N = 423).
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women (OR: 1.27, 95% CI: 0.50–3.23, P = 0.61). Similarly,
the prevalence of any histological evidence of acute, chronic,
or past placental malaria was similar between HbAS (26.9%)
and HbAA (27.5%) women (OR: 0.97, 95% CI: 0.40–2.34,
P = 0.95) (Table 2).
There was a significantly higher prevalence by real-time
PCR of peripheral P. falciparum in HbAS (20%) than
HbAA (8%) women (OR: 2.53, 95% CI: 1.08–5.94, P =
0.03) (Table 2). We hypothesized that HbAS may permit
peripheral parasite propagation while specifically prevent-
ing placental sequestration, and we tested this by quanti-
fying the ratio of parasite densities in the placental and
peripheral blood in women who were concurrently infected
in both compartments. After quantifying parasite densities
in matched blood samples from 71 HbAA and five HbAS
women and computing placental density ratios, there was no
evidence of reduced placental sequestration in HbAS women
(Table 2).
The prevalence of LBW was similar among newborns
born to HbAS (9.4%) and HbAA (11.3%) women (OR:
0.82, 95% CI: 0.24–2.73, P = 0.74) (Table 2). Similarly, mean
(SD) birth weights were similar in newborns born to HbAS
(2,947 g [563]) and HbAA (2,991 g [465]) women, and dis-
tributions of birth weight did not appear to differ by the
mother’s HBB genotype (Figure 3).
DISCUSSION
In this cross-sectional study of delivering women in Malawi,
HbAS did not confer protection from placental malaria or
from its consequences. There were no significant differ-
ences between women with and without HbAS on placental
or peripheral P. falciparum prevalence, placental parasite
density, histological evidence of placental infection or inflam-
mation, or birth weight. Although the low prevalence of
HbAS undoubtedly limited our ability to detect differences,
the absence of any apparent effect across a broad range of
parasitological, histological, and clinical outcomes suggests
that HbAS likely does not affect the ability of P. falciparum-
infected RBCs to accumulate in the placenta.
We hypothesized that HbAS would reduce the risk of pla-
cental malaria. This hypothesis was predicated on in vitro
evidence that HbAS attenuates the binding of infected RBCs
to microvascular endothelium, possibly by quantitatively
or qualitatively affecting the expression of PfEMP1 on the
iRBC surface.18–20 Because the conserved PfEMP1 protein
VAR2CSA is the principal parasite ligand that enables pla-
cental sequestration of iRBCs in vivo,8,10 HbAS could be
expected to also disrupt iRBC binding to CSA in the
syncytiotrophoblast. However, we found no evidence of
these effects.
Why did HbAS fail to prevent placental malaria? Aberrant
expression of PfEMP1 on the HbAS iRBC surface might still
permit CSA binding owing to the lower flow conditions of the
intervillous space (relative to the microvasculature)21 or to
the high affinity of VAR2CSA for CSA.22 HbAS may restrict
the expression only of specific PfEMP1 variants on the iRBC
surface while permitting VAR2CSA expression, although this
is not supported by recent evidence that a shared parasite
protein export machinery traffics VAR2CSA as well as other
surface antigens to the erythrocyte membrane.23 Alternatively,
aberrant PfEMP1 expression may be less disruptive to the
specific VAR2CSA–CSA interaction than it is to the binding
of PfEMP1 to a myriad of endothelial receptors. Finally, there
may broadly exist differences in quality between iRBC bind-
ing to CSA and to endothelium, with the latter characterized
by varieties of receptors and parasite ligands as well as an
active dialogue between iRBC and activated endothelium.
There was no clear association between maternal HbAS
and birth weight (Table 2 and Figure 3). Although the preva-
lence of LBW was slightly lower among newborns born
to women with HbAS (9.4%) than with HbAA (11.3%)
(Table 2), this difference was not statistically significant, and
mean birth weight overall was 44 g lower in births to women
with HbAS (Figure 3). Prior studies of the association between
HbAS and birth weight have yielded mixed results: in some
studies, reduced birth weight is more frequent in newborns
born to HbAS women,24–26 while in others there was no differ-
ence between women with HbAS and HbAA,27–31 including
in two Nigerian studies in malaria-endemic settings.32,33 Taken
together with our data, HbAS does not appear to consistently
impact newborn birth weight, and nor does this relationship
appear to be modified by malaria endemicity.
Consistent with prior studies, placental malaria was asso-
ciated with first pregnancy and with lower birth weight
(Figure 2). The higher susceptibility of primigravidae to
placental malaria is well described,34 as is the association
between placental parasite infection and LBW (Figure 1).
Our study has several potential limitations. The low preva-
lence of the HbS allele limited our ability to detect small
differences in outcomes; to mitigate the risk of a type II
error, we used a large patient cohort and analyzed a broad
range of outcomes. We could not assess ex vivo pheno-
types of placental or CSA binding of the placental para-
sites, and therefore we cannot directly measure the effect
of HbAS on placental sequestration. Similarly, we cannot
confirm that the concentration of CSA in the syncytio-
trophoblast is unaffected by HbAS. Finally, our analyses
of birth weight may have been confounded by newborn
genotype, because newborn HbSS is associated with LBW;
however, the low HbS allele prevalence suggests that few
offspring harbored HbSS.
FIGURE 3. Kernel density plots of infant birth weight by sickle
cell trait (heterozygous hemoglobin S [AS] vs. homozygous hemo-
globin A [AA]).
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In our cross-sectional study of delivering women in a high-
transmission setting in Malawi, HbAS was not associated
with a reduced risk of placental malaria or LBW. Although
HbAS confers substantial protection from severe malaria in
children and reduces cytoadherence in vitro, these data sug-
gest that HbAS does not attenuate the ability of infected
RBCs to accumulate in the placenta.
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